Brief report

A phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study

Thanyanan Reungwetwattana, Julian R Molina, Sumithra J Mandrekar, Katie Allen-Ziegler, Kendrith M. Rowland, Nicholas F. Reuter, Ronnie F. Luyun, Grace K. Dy, Randolph Stuart Marks, Steven E. Schild, James R. Jett, Alex Adjei

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: In an effort to evaluate the single agent activity of temsirolimus in previously untreated non-small-cell lung cancer, the North Central Cancer Treatment Group undertook a frontline "window- of-opportunity" study. Methods: Patients received 25 mg of temsirolimus administered intravenously as a weekly 30 minute infusion, on a 4-week cycle. Based on a two-stage Fleming design, the treatment would be promising if at least four of the first 25 evaluable patients in stage I or at least six of the 50 evaluable patients at the end of stage II have a confirmed response. Fresh tumor biopsies were obtained to evaluate predictive markers of temsirolimus activity. Results: A total of 55 patients were enrolled with 52 patients being evaluable. The median age was 64 years. Adverse events (grade 3/4) occurring in 33 patients included dyspnea (12%), fatigue (10%), hyperglycemia (8%), hypoxia (8%), nausea (8%), and rash/desquamation (6%). The clinical benefit rate was 35% with four patients achieving a confirmed partial response and 14 patients with stable disease for 8 weeks or more. The 24-week progression-free survival rate was 25%. Median progression-free survival and overall survival were 2.3 and 6.6 months, respectively. Expression of p70s6 kinase, phospho-p70s6 kinase, Akt, phospho-Akt, and phosphatase and tensin homolog mutation did not correlate with clinical outcome. Conclusions: Temsirolimus given as a single agent in frontline therapy in patients with non-small-cell lung cancer was tolerable and demonstrated clinical benefit but did not meet the primary objective in this study. Patient selection will be needed to enhance the efficacy.

Original languageEnglish (US)
Pages (from-to)919-922
Number of pages4
JournalJournal of Thoracic Oncology
Volume7
Issue number5
DOIs
StatePublished - 2012

Fingerprint

Proxy
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Phosphotransferases
temsirolimus
Exanthema
Phosphoric Monoester Hydrolases
Hyperglycemia
Dyspnea
Nausea
Patient Selection
Fatigue
Neoplasms
Therapeutics
Survival Rate
Biopsy
Mutation
Survival

Keywords

  • Advanced non-small-cell lung carcinoma
  • MTOR inhibitors
  • Temsirolimus
  • Window of opportunity

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Brief report : A phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. / Reungwetwattana, Thanyanan; Molina, Julian R; Mandrekar, Sumithra J; Allen-Ziegler, Katie; Rowland, Kendrith M.; Reuter, Nicholas F.; Luyun, Ronnie F.; Dy, Grace K.; Marks, Randolph Stuart; Schild, Steven E.; Jett, James R.; Adjei, Alex.

In: Journal of Thoracic Oncology, Vol. 7, No. 5, 2012, p. 919-922.

Research output: Contribution to journalArticle

Reungwetwattana, Thanyanan ; Molina, Julian R ; Mandrekar, Sumithra J ; Allen-Ziegler, Katie ; Rowland, Kendrith M. ; Reuter, Nicholas F. ; Luyun, Ronnie F. ; Dy, Grace K. ; Marks, Randolph Stuart ; Schild, Steven E. ; Jett, James R. ; Adjei, Alex. / Brief report : A phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. In: Journal of Thoracic Oncology. 2012 ; Vol. 7, No. 5. pp. 919-922.
@article{858f4ef0c77a413bae925963afb9eb18,
title = "Brief report: A phase II {"}window-of-opportunity{"} frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study",
abstract = "Background: In an effort to evaluate the single agent activity of temsirolimus in previously untreated non-small-cell lung cancer, the North Central Cancer Treatment Group undertook a frontline {"}window- of-opportunity{"} study. Methods: Patients received 25 mg of temsirolimus administered intravenously as a weekly 30 minute infusion, on a 4-week cycle. Based on a two-stage Fleming design, the treatment would be promising if at least four of the first 25 evaluable patients in stage I or at least six of the 50 evaluable patients at the end of stage II have a confirmed response. Fresh tumor biopsies were obtained to evaluate predictive markers of temsirolimus activity. Results: A total of 55 patients were enrolled with 52 patients being evaluable. The median age was 64 years. Adverse events (grade 3/4) occurring in 33 patients included dyspnea (12{\%}), fatigue (10{\%}), hyperglycemia (8{\%}), hypoxia (8{\%}), nausea (8{\%}), and rash/desquamation (6{\%}). The clinical benefit rate was 35{\%} with four patients achieving a confirmed partial response and 14 patients with stable disease for 8 weeks or more. The 24-week progression-free survival rate was 25{\%}. Median progression-free survival and overall survival were 2.3 and 6.6 months, respectively. Expression of p70s6 kinase, phospho-p70s6 kinase, Akt, phospho-Akt, and phosphatase and tensin homolog mutation did not correlate with clinical outcome. Conclusions: Temsirolimus given as a single agent in frontline therapy in patients with non-small-cell lung cancer was tolerable and demonstrated clinical benefit but did not meet the primary objective in this study. Patient selection will be needed to enhance the efficacy.",
keywords = "Advanced non-small-cell lung carcinoma, MTOR inhibitors, Temsirolimus, Window of opportunity",
author = "Thanyanan Reungwetwattana and Molina, {Julian R} and Mandrekar, {Sumithra J} and Katie Allen-Ziegler and Rowland, {Kendrith M.} and Reuter, {Nicholas F.} and Luyun, {Ronnie F.} and Dy, {Grace K.} and Marks, {Randolph Stuart} and Schild, {Steven E.} and Jett, {James R.} and Alex Adjei",
year = "2012",
doi = "10.1097/JTO.0b013e31824de0d6",
language = "English (US)",
volume = "7",
pages = "919--922",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "5",

}

TY - JOUR

T1 - Brief report

T2 - A phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study

AU - Reungwetwattana, Thanyanan

AU - Molina, Julian R

AU - Mandrekar, Sumithra J

AU - Allen-Ziegler, Katie

AU - Rowland, Kendrith M.

AU - Reuter, Nicholas F.

AU - Luyun, Ronnie F.

AU - Dy, Grace K.

AU - Marks, Randolph Stuart

AU - Schild, Steven E.

AU - Jett, James R.

AU - Adjei, Alex

PY - 2012

Y1 - 2012

N2 - Background: In an effort to evaluate the single agent activity of temsirolimus in previously untreated non-small-cell lung cancer, the North Central Cancer Treatment Group undertook a frontline "window- of-opportunity" study. Methods: Patients received 25 mg of temsirolimus administered intravenously as a weekly 30 minute infusion, on a 4-week cycle. Based on a two-stage Fleming design, the treatment would be promising if at least four of the first 25 evaluable patients in stage I or at least six of the 50 evaluable patients at the end of stage II have a confirmed response. Fresh tumor biopsies were obtained to evaluate predictive markers of temsirolimus activity. Results: A total of 55 patients were enrolled with 52 patients being evaluable. The median age was 64 years. Adverse events (grade 3/4) occurring in 33 patients included dyspnea (12%), fatigue (10%), hyperglycemia (8%), hypoxia (8%), nausea (8%), and rash/desquamation (6%). The clinical benefit rate was 35% with four patients achieving a confirmed partial response and 14 patients with stable disease for 8 weeks or more. The 24-week progression-free survival rate was 25%. Median progression-free survival and overall survival were 2.3 and 6.6 months, respectively. Expression of p70s6 kinase, phospho-p70s6 kinase, Akt, phospho-Akt, and phosphatase and tensin homolog mutation did not correlate with clinical outcome. Conclusions: Temsirolimus given as a single agent in frontline therapy in patients with non-small-cell lung cancer was tolerable and demonstrated clinical benefit but did not meet the primary objective in this study. Patient selection will be needed to enhance the efficacy.

AB - Background: In an effort to evaluate the single agent activity of temsirolimus in previously untreated non-small-cell lung cancer, the North Central Cancer Treatment Group undertook a frontline "window- of-opportunity" study. Methods: Patients received 25 mg of temsirolimus administered intravenously as a weekly 30 minute infusion, on a 4-week cycle. Based on a two-stage Fleming design, the treatment would be promising if at least four of the first 25 evaluable patients in stage I or at least six of the 50 evaluable patients at the end of stage II have a confirmed response. Fresh tumor biopsies were obtained to evaluate predictive markers of temsirolimus activity. Results: A total of 55 patients were enrolled with 52 patients being evaluable. The median age was 64 years. Adverse events (grade 3/4) occurring in 33 patients included dyspnea (12%), fatigue (10%), hyperglycemia (8%), hypoxia (8%), nausea (8%), and rash/desquamation (6%). The clinical benefit rate was 35% with four patients achieving a confirmed partial response and 14 patients with stable disease for 8 weeks or more. The 24-week progression-free survival rate was 25%. Median progression-free survival and overall survival were 2.3 and 6.6 months, respectively. Expression of p70s6 kinase, phospho-p70s6 kinase, Akt, phospho-Akt, and phosphatase and tensin homolog mutation did not correlate with clinical outcome. Conclusions: Temsirolimus given as a single agent in frontline therapy in patients with non-small-cell lung cancer was tolerable and demonstrated clinical benefit but did not meet the primary objective in this study. Patient selection will be needed to enhance the efficacy.

KW - Advanced non-small-cell lung carcinoma

KW - MTOR inhibitors

KW - Temsirolimus

KW - Window of opportunity

UR - http://www.scopus.com/inward/record.url?scp=84862133526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862133526&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31824de0d6

DO - 10.1097/JTO.0b013e31824de0d6

M3 - Article

VL - 7

SP - 919

EP - 922

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 5

ER -